| NIH
Pharmacogenomics Grants, August — September 2006 |
|
Organization
Name
|
Award
|
Principal
Investigator
|
Title
|
| University
of North Carolina, Chapel Hill |
$151,982
|
Zhen Lin
|
Protecting
Genetic Privacy through Risk Assessment |
| Prediction
Sciences |
$242,805
|
Troy Bremer
|
SNP-based
lithium treatment outcome diagnostic |
| Queensland
Institute of Medical Research |
$399,696
|
Grant Montgomery
|
Identifying
Susceptibility Genes for Endometriosis |
| Children's
Hospital Pittsburgh |
$372,108
|
Rakesh Sindhi
|
Predictors
for drug selection and minimization in pediatric liver transplantation |
| Maxwell
Sensors |
$103,520
|
Margaret Morgan
|
A
Parallel High-Throughput Pharmacogenetic Profiling Assay for Clinical Use |
| Roswell
Park Cancer Institute |
$99,750
|
Kirsten Moysich
|
Pharmacogenetics
in Ovarian Cancer |
| Brigham
and Women's Hospital |
$161,750
|
Kelan Tantisira
|
Pharmacogenetic
Linkage of Corticosteroid Response: Asthma Therapy Implications |
| Marshfield
Clinic Research Foundation |
NA
|
Michael
Caldwell
|
Modeling
Genotype and other Factors to Enhance the Safety of Warfarin Prescribing |
| Boston
University |
$257,629
|
Timothy Lash
|
Modification
of tamoxifen effectiveness by gene polymorphisms and other drugs |
| Harvard
University |
$82,000
|
Wei Zhou
|
Serum
25(OH)D levels, VDR and CYP24 polymorphisms, and NSCLC survival |
| Physiogenix
|
$392,306
|
Steven Nye
|
Consomic
rat panels for pharmacogenomic studies and target identification |
| Roswell
Park Cancer Institute |
$638,179
|
Christine Ambrosone
|
Antioxidant
supplements, genetics, and chemotherapy outcomes |
|
*SOURCE:
US National Institutes of Health
|